Accepted for Publication: April 14, 2012.
Published Online: June 18, 2012. doi:10.1001/archdermatol.2012.1522
Author Contributions: Drs Lunardon, Stanley, Tsai, and Payne had full access to all the data and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Lunardon, Stanley, and Payne. Acquisition of data: K. J. Tsai, Fett, Stanley, Werth, D. E. Tsai, and Payne. Analysis and interpretation of data: Lunardon, Propert, Stanley, Werth, and Payne. Drafting of the manuscript: Lunardon, Propert, and Payne. Critical revision of the manuscript for important intellectual content: K. J. Tsai, Propert, Fett, Stanley, Werth, D. E. Tsai, and Payne. Statistical analysis: Propert. Obtained funding: Payne. Administrative, technical, and material support: Lunardon, K. J. Tsai, D. E. Tsai, and Payne. Study supervision: Payne.
Financial Disclosure: Dr Tsai reports that he has partial stock ownership of Biogen IDEC. Dr Werth reports that she serves as a consultant for Lupus Foundation of America, Pfizer, Medimmune, Genentech, Novartis, Celgene, Stiefel, Rigel, Astion, Amgen, Infinity Pharmaceuticals, sanofi-aventis, and UBC; has research grants from Amgen and Celgene; and has partial stock ownership of UV Therapeutics; and that University of Pennsylvania holds the copyright for the Cutaneous Lupus Erythematosus Disease Area and Severity Index and the Cutaneous Disease and Activity Severity Index.
Funding/Support: This work was supported by the Department of Dermatology, University of Milan, Milan, Italy (Dr Lunardon), and grants AR052672 (Dr Stanley), AR002207 (Dr Werth), AR053505 and AR057001 (Dr Payne), CTSA UL1-RR-024134 (Dr Propert), and Skin Disease Research Center grant AR057217 (Drs Stanley and Payne) from the National Institutes of Health, Bethesda, Maryland.